Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.87 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.93 |
| ▸ | CA12 | O43570 | 5/20 | 0.87 |
| ▸ | CA6 | P23280 | 5/20 | 0.87 |
| ▸ | CA7 | P43166 | 5/20 | 0.87 |
| ▸ | CA9 | Q16790 | 5/20 | 0.87 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.87 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.87 |
| ▸ | CA4 | P22748 | 4/20 | 0.87 |
| ▸ | CA5A | P35218 | 4/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.87 |
| ▸ | CA3 | P07451 | 3/20 | 0.87 |
| ▸ | F13A1 | P00488 | 2/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.87 |
| ▸ | THPO | P40225 | 2/20 | 0.87 |
| ▸ | CA1 | P00915 | 2/20 | 0.87 |
| ▸ | UBE2N | P61088 | 1/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29380039 | 1.00 | LMNA (0.93) | LMNASMN1; SMN2CA12CA6CA7 | |
| Hydrochloric Acid SCHEMBL30866180 | 1.00 | LMNA (0.93) | LMNASMN1; SMN2CA12CA6CA7 | |
| Hydrochloric Acid SCHEMBL7521533 | 0.97 | LMNA (0.88) | LMNASMN1; SMN2CA12CA6CA7 | |
| Hydrochloric Acid SCHEMBL153901 | 0.97 | LMNA (0.88) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL3623585 | 0.97 | LMNA (1.00) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL343877 | 0.97 | LMNA (1.00) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL573651 | 0.97 | LMNA (1.00) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL7928492 | 0.97 | LMNA (1.00) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL573341 | 0.97 | LMNA (1.00) | LMNASMN1; SMN2CA12CA6CA7 | |
| Hydrochloric Acid SCHEMBL7515358 | 0.97 | LMNA (0.88) | LMNASMN1; SMN2CA12CA6CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115820591-B | High spermidine synthetase mutant and application thereof | 江南大学 | 2025-06-03 | — | — | CN | claimed |
| WO-2025070707-A1 | COMPOSITION CONTAINING DIAMINE AND/OR POLYAMINE FOR PREVENTING OR IMPROVING FRAILTY | 東洋紡株式会社 | 2025-04-03 | — | — | WO | claimed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | claimed |
| CN-112997885-B | Induction medium for adventitious buds of tulip | 辽宁省农业科学院 | 2023-06-06 | — | — | CN | claimed |
| US-20220313625-A1 | PHARMACEUTICAL AGENT, MEDICINAL SOLUTION FOR CLEANING PULMONARY ALVEOLI, AND NEBULIZER | OHKIDO, MAKIKO (JP) | 2022-10-06 | — | — | US | claimed |
| US-12365659-B2 | Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| CN-115820591-B | High spermidine synthetase mutant and application thereof | 江南大学 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025070707-A1 | COMPOSITION CONTAINING DIAMINE AND/OR POLYAMINE FOR PREVENTING OR IMPROVING FRAILTY | 東洋紡株式会社 | 2025-04-03 | — | — | WO | disclosed |
| CN-119685278-A | Multienzyme cascade catalysis method for synthesizing spermidine | 上海健力达生物科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-12213503-B2 | Method of treating plant and method of making plant-based food or drink product | NICHIA CORPORATION (JP) | 2025-02-04 | — | — | US | disclosed |
| US-20250001399-A1 | CELL ADSORPTION MATERIAL AND CELL ADSORPTION COLUMN | TORAY INDUSTRIES, INC. (JP) | 2025-01-02 | — | — | US | disclosed |
| CN-115612699-B | Copolymer membrane, and enzymatic self-assembly synthesis method and application thereof in gas-liquid interface | 中国科学院天津工业生物技术研究所 | 2024-10-25 | — | — | CN | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-109563158-B | Anti-complement factor BB antibodies and uses thereof | 比奥贝拉蒂美国公司 | 2022-08-09 | — | — | CN | disclosed |
| US-20220162561-A1 | COMPOSITION FOR PROMOTING SECRETION OF EXTRACELLULAR VESICLES | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-26 | — | — | US | disclosed |
| CN-114340671-A | Antibodies specific for GPC3 and methods of use thereof | R.P.谢勒技术有限责任公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3971178-A1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | The McLean Hospital Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220064133-A1 | ANTHRANILIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | Sanford Burnham Prebys Medical Discovery Institute | 2022-03-03 | — | — | US | disclosed |
| CN-111278483-B | Immunosuppressive leukocyte adsorption material and adsorption column | 东丽株式会社 | 2022-03-01 | — | — | CN | disclosed |
| US-20220039437-A1 | METHOD OF TREATING PLANT AND METHOD OF MAKING PLANT-BASED FOOD OR DRINK PRODUCT | NICHIA CORPORATION (JP) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064133-A1 | ANTHRANILIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | ENY2, ANTXR2, ALAD | CA2 1552/4885ESR1 729/4885LMNA 1859/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | CA2 504/4885ESR1 3995/4885LMNA 1830/4885 |
| US-12365659-B2 | Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers | SLC19A1, PNMT, SRM | CA2 1070/4885ESR1 3946/4885LMNA 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.